 |
인쇄하기
취소
|
Binex buys 22% stake in Aprogen
Binex Co. has bought a 22 percent stake in Aprogen from Schnell Biopharmaceuticals for 16 billion won to take lead in biosimilars, industry sources said Wednesday.
Biosimilars, or imitation biopharmaceuticals, are officially approved subsequent versions of innovative biopharmaceutical products manufactured by different producers after the patent on the innovator product expires.
Aprogen p...
Biosimilars, or imitation biopharmaceuticals, are officially approved subsequent versions of innovative biopharmaceutical products manufactured by different producers after the patent on the innovator product expires.
Aprogen p...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.